Published in Cancer Immunol Immunother on March 26, 2014
Bacteria in Cancer Therapy: Renaissance of an Old Concept. Int J Microbiol (2016) 0.95
Salmonella as an innovative therapeutic antitumor agent. Int J Mol Sci (2014) 0.85
Efficiency of conditionally attenuated Salmonella enterica serovar Typhimurium in bacterium-mediated tumor therapy. MBio (2015) 0.84
Salmonella typhimurium Suppresses Tumor Growth via the Pro-Inflammatory Cytokine Interleukin-1β. Theranostics (2015) 0.82
Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma. PLoS One (2014) 0.81
Salmonella inhibits tumor angiogenesis by downregulation of vascular endothelial growth factor. Oncotarget (2016) 0.76
Solid tumors provide niche-specific conditions that lead to preferential growth of Salmonella. Oncotarget (2016) 0.76
Deficiency of mitochondrial modulator MCJ promotes chemoresistance in breast cancer. JCI Insight (2016) 0.75
Therapeutic benefit of Salmonella attributed to LPS and TNF-α is exhaustible and dictated by tumor susceptibility. Oncotarget (2017) 0.75
Cholinergic Stimulation Prevents the Development of Autoimmune Diabetes: Evidence for the Modulation of Th17 Effector Cells via an IFNγ-Dependent Mechanism. Front Immunol (2016) 0.75
The genes slyA, STM3120 and htrA are required for the anticancer ability of VNP20009. Oncotarget (2016) 0.75
Salmonella-Mediated Cancer Therapy: Roles and Potential. Nucl Med Mol Imaging (2016) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Noncoding RNA gas5 is a growth arrest- and starvation-associated repressor of the glucocorticoid receptor. Sci Signal (2010) 4.77
PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med (2014) 2.51
Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin Dev Immunol (2012) 1.75
Myeloid-derived suppressor cells in cancer: recent progress and prospects. Immunol Cell Biol (2013) 1.50
Human mesenchymal stem cells derived from induced pluripotent stem cells down-regulate NK-cell cytolytic machinery. Blood (2011) 1.43
Alpha E beta 7 integrin interaction with E-cadherin promotes antitumor CTL activity by triggering lytic granule polarization and exocytosis. J Exp Med (2007) 1.42
Tumor-associated macrophages (TAMs) form an interconnected cellular supportive network in anaplastic thyroid carcinoma. PLoS One (2011) 1.39
Bead-isolated human CD4+CD25+ T regulatory cells are anergic and significantly suppress proliferation of CD4+CD25- T responder cells. Clin Immunol (2006) 1.38
Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis. Cancer Res (2013) 1.36
The cooperative induction of hypoxia-inducible factor-1 alpha and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis. J Immunol (2009) 1.32
Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother (2007) 1.32
Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. Cancer Res (2012) 1.30
Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma. J Immunol (2005) 1.30
Host and viral factors associated with severity of human rhinovirus-associated infant respiratory tract illness. J Allergy Clin Immunol (2011) 1.27
High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest (2004) 1.26
Blocking hypoxia-induced autophagy in tumors restores cytotoxic T-cell activity and promotes regression. Cancer Res (2011) 1.25
Membrane-bound and soluble IL-15/IL-15Ralpha complexes display differential signaling and functions on human hematopoietic progenitors. Blood (2005) 1.22
ICAM-1 has a critical role in the regulation of metastatic melanoma tumor susceptibility to CTL lysis by interfering with PI3K/AKT pathway. Cancer Res (2008) 1.15
Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin Cancer Res (2010) 1.14
Viral etiologies of infant bronchiolitis, croup and upper respiratory illness during 4 consecutive years. Pediatr Infect Dis J (2013) 1.13
Prion protein prevents human breast carcinoma cell line from tumor necrosis factor alpha-induced cell death. Cancer Res (2004) 1.10
Cytotoxic T lymphocytes directed against a tumor-specific mutated antigen display similar HLA tetramer binding but distinct functional avidity and tissue distribution. Proc Natl Acad Sci U S A (2002) 1.09
HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol (2002) 1.06
EphA2 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes. Cancer Res (2003) 1.06
Neuropilin 1: function and therapeutic potential in cancer. Cancer Immunol Immunother (2013) 1.05
Differentiation therapy: targeting human renal cancer stem cells with interleukin 15. J Natl Cancer Inst (2011) 1.05
Clinical and immunologic results of a phase II trial of sequential imiquimod and photodynamic therapy for vulval intraepithelial neoplasia. Clin Cancer Res (2008) 1.05
Microenvironmental hypoxia orchestrating the cell stroma cross talk, tumor progression and antitumor response. Crit Rev Immunol (2011) 1.04
T cell-based immunotherapy of metastatic renal cell carcinoma: modest success and future perspective. Clin Cancer Res (2009) 1.04
Engagement of the inhibitory receptor CD158a interrupts TCR signaling, preventing dynamic membrane reorganization in CTL/tumor cell interaction. Blood (2002) 1.03
The acquisition of resistance to TNFα in breast cancer cells is associated with constitutive activation of autophagy as revealed by a transcriptome analysis using a custom microarray. Autophagy (2011) 1.02
Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy. J Immunol (2002) 1.01
NK cells infiltrating a MHC class I-deficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors. J Immunol (2005) 1.01
Intratumoral induction of CD103 triggers tumor-specific CTL function and CCR5-dependent T-cell retention. Cancer Res (2009) 0.99
Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells. Clin Immunol (2010) 0.99
CD158 receptor controls cytotoxic T-lymphocyte susceptibility to tumor-mediated activation-induced cell death by interfering with Fas signaling. Cancer Res (2003) 0.97
Cross-talk between Smad and p38 MAPK signalling in transforming growth factor beta signal transduction in human glioblastoma cells. Biochem Biophys Res Commun (2007) 0.97
Silencing of prion protein sensitizes breast adriamycin-resistant carcinoma cells to TRAIL-mediated cell death. Cancer Res (2007) 0.97
Identification of target actin content and polymerization status as a mechanism of tumor resistance after cytolytic T lymphocyte pressure. Proc Natl Acad Sci U S A (2006) 0.97
Mutant alpha-actinin-4 promotes tumorigenicity and regulates cell motility of a human lung carcinoma. Oncogene (2004) 0.96
Prevention of autoimmunity and control of recall response to exogenous antigen by Fas death receptor ligand expression on T cells. Immunity (2008) 0.96
Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia. Proc Natl Acad Sci U S A (2013) 0.96
Potent anti-tumor activity of systemically-administered IL2-expressing Salmonella correlates with decreased angiogenesis and enhanced tumor apoptosis. Clin Immunol (2008) 0.96
Human CD5 protects circulating tumor antigen-specific CTL from tumor-mediated activation-induced cell death. J Immunol (2007) 0.95
STEAP, a prostate tumor antigen, is a target of human CD8+ T cells. Cancer Immunol Immunother (2006) 0.93
EMT impairs breast carcinoma cell susceptibility to CTL-mediated lysis through autophagy induction. Autophagy (2013) 0.93
Sex hormone-binding globulin gene expression in the liver: drugs and the metabolic syndrome. Mol Cell Endocrinol (2009) 0.93
A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor. J Exp Med (2011) 0.92
Phenotypic alterations, clinical impact and therapeutic potential of regulatory T cells in cancer. Expert Opin Biol Ther (2014) 0.92
Cutting edge: Hypoxia-induced Nanog favors the intratumoral infiltration of regulatory T cells and macrophages via direct regulation of TGF-β1. J Immunol (2013) 0.91
In situ sensory adaptation of tumor-infiltrating T lymphocytes to peptide-MHC levels elicits strong antitumor reactivity. J Immunol (2005) 0.91
Hypoxia-induced autophagy: a new player in cancer immunotherapy? Autophagy (2012) 0.91
Activation of cytotoxic T-cell receptor gammadelta T lymphocytes in response to specific stimulation in myelodysplastic syndromes. Haematologica (2008) 0.91
Antitumor cytotoxic T-lymphocyte response in human lung carcinoma: identification of a tumor-associated antigen. Immunol Rev (2002) 0.91
Generation of a novel regulatory NK cell subset from peripheral blood CD34+ progenitors promoted by membrane-bound IL-15. PLoS One (2008) 0.90
Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cell carcinoma patients. J Immunother (2008) 0.90
TLR ligands stimulation protects MSC from NK killing. Stem Cells (2014) 0.90
Hypoxia-dependent inhibition of tumor cell susceptibility to CTL-mediated lysis involves NANOG induction in target cells. J Immunol (2011) 0.90
Human renal cancer cells express a novel membrane-bound interleukin-15 that induces, in response to the soluble interleukin-15 receptor alpha chain, epithelial-to-mesenchymal transition. Cancer Res (2009) 0.90
Potentiation of NK cell-mediated cytotoxicity in human lung adenocarcinoma: role of NKG2D-dependent pathway. Int Immunol (2008) 0.89
Cytokeratin 18 expression pattern correlates with renal cell carcinoma progression: relationship with Snail. Int J Oncol (2010) 0.89
The decreased susceptibility of Bcr/Abl targets to NK cell-mediated lysis in response to imatinib mesylate involves modulation of NKG2D ligands, GM1 expression, and synapse formation. J Immunol (2006) 0.89
Two opposite signaling outputs are driven by the KIR2DL1 receptor in human CD4+ T cells. Blood (2008) 0.89
Helios expression in FoxP3(+) T regulatory cells. Expert Opin Biol Ther (2012) 0.87
Membrane-bound interleukin (IL)-15 on renal tumor cells rescues natural killer cells from IL-2 starvation-induced apoptosis. Cancer Res (2007) 0.87
Crosstalk between CTC, Immune System and Hypoxic Tumor Microenvironment. Cancer Microenviron (2014) 0.87
Silencing of the transcription factor STAT3 sensitizes lung cancer cells to DNA damaging drugs, but not to TNFα- and NK cytotoxicity. Exp Cell Res (2012) 0.87
A three-dimensional tumor cell defect in activating autologous CTLs is associated with inefficient antigen presentation correlated with heat shock protein-70 down-regulation. Cancer Res (2003) 0.86
Adoptive transfer of T(reg) depleted autologous T cells in advanced renal cell carcinoma. Cancer Immunol Immunother (2007) 0.85
Interleukin-15 plays a central role in human kidney physiology and cancer through the γc signaling pathway. PLoS One (2012) 0.85
Preprocalcitonin signal peptide generates a cytotoxic T lymphocyte-defined tumor epitope processed by a proteasome-independent pathway. Proc Natl Acad Sci U S A (2008) 0.85
CD154 is essential for protective immunity in experimental salmonella infection: evidence for a dual role in innate and adaptive immune responses. J Immunol (2006) 0.85
Attenuated bacteria as effectors in cancer immunotherapy. Ann N Y Acad Sci (2008) 0.84
Macrophage inhibitory cytokine-1: a review of its pleiotropic actions in cancer. Cancer Biomark (2012) 0.84
Cytotoxic T cells - stroma interactions. Bull Cancer (2011) 0.84
Human NK cells lyse organ-specific endothelial cells: analysis of adhesion and cytotoxic mechanisms. J Immunol (2005) 0.83
Comment on "Expression of Helios in peripherally induced Foxp3+ regulatory T cells". J Immunol (2012) 0.83
The chemokine SDF-1/CXCL12 contributes to T lymphocyte recruitment in human pre-ovulatory follicles and coordinates with lymphocytes to increase granulosa cell survival and embryo quality. Am J Reprod Immunol (2005) 0.83
CD8 T-cell recognition of human 5T4 oncofetal antigen. Int J Cancer (2006) 0.83
Cytotoxic dendritic cells generated from cancer patients. J Immunol (2011) 0.83
Interleukin-15 is a major regulator of the cell-microenvironment interactions in human renal homeostasis. Cytokine Growth Factor Rev (2012) 0.83
Analysis of the natural killer mediated immune response in metastatic renal cell carcinoma patients. Int J Cancer (2004) 0.82
The actin filament cross-linker L-plastin confers resistance to TNF-alpha in MCF-7 breast cancer cells in a phosphorylation-dependent manner. J Cell Mol Med (2009) 0.82
Inducible Hsp70 as target of anticancer immunotherapy: Identification of HLA-A*0201-restricted epitopes. Int J Cancer (2004) 0.82
Novel expression of Neuropilin 1 on human tumor-infiltrating lymphocytes in colorectal cancer liver metastases. Expert Opin Ther Targets (2014) 0.81
The anti-angiogenic activity of IL-12 is increased in iNOS-/- mice and involves NK cells. J Mol Med (Berl) (2010) 0.81
Leukemic target susceptibility to natural killer cytotoxicity: relationship with BCR-ABL expression. Blood (2002) 0.81
A polyepitope DNA vaccine targeted to Her-2/ErbB-2 elicits a broad range of human and murine CTL effectors to protect against tumor challenge. Cancer Res (2007) 0.81
The autophagy sensor ITPR1 protects renal carcinoma cells from NK-mediated killing. Autophagy (2015) 0.81
Off-target effects of plasmid-transcribed shRNAs on NFκB signaling pathway and cell survival of human melanoma cells. Mol Biol Rep (2013) 0.80
5T4 as a target for immunotherapy in renal cell carcinoma. Expert Rev Anticancer Ther (2009) 0.80
p53 potentiation of tumor cell susceptibility to CTL involves Fas and mitochondrial pathways. J Immunol (2005) 0.79
Gap junction communication between autologous endothelial and tumor cells induce cross-recognition and elimination by specific CTL. J Immunol (2009) 0.79
Opposite effects of estrogen receptors alpha and beta on MCF-7 sensitivity to the cytotoxic action of TNF and p53 activity. Oncogene (2005) 0.79